16 research outputs found
Waninger, Wm. R. (Birth, 1899-01-13)
No full textAddress: 13 Corry St.392/Pg 8/1899/M W/Germany/Cinti/Dr. E. J. BatchelorOriginal record filed in drawer labeled 'WALTER- WARMACK'
Targeting RAS and EGFR Driven Cancers
No full textMutations in members of the MAPK pathway are heavily implicated in cancer initiation and progression. Normal pathway activation begins at the cell surface where the epidermal growth factor receptor (EGFR) receives input from the extracellular environment and initiates the activation of downstream signaling molecules like RAS. RAS proteins are small GTPases that act as molecular switches by cycling through a GTP-on and GDP-off state. Mutations in RAS members contribute to one-third of all cancers, including some of the most aggressive and lethal tumor types like those of the pancreas, lung, and colon. Clinically targeting mutant RAS proteins and the cancers they promote have been the object of intense research for decades, yet patient’s harboring these mutations still have few treatment options. Here we describe two disparate mechanisms for treating RAS-driven cancers. First, we describe the characterization of a new binding partner of RAS, Argonaute 2 (AGO2), that facilitates its oncogenic potential. AGO2 is the catalytic component of the RNA induced silencing complex (RISC) and a crucial mediator of RNA interference in the cell. Previous work demonstrated that AGO2 associates with RAS and facilitates oncogenesis. Furthermore, loss of AGO2 was shown to prevent tumor progression by initiating oncogene induced senescence. Whereas previous studies described the in vivo effect of AGO2 on cancer progression and demonstrated the AGO2–KRAS association in cells, here I have examined their interaction at the biochemical level. Using purified proteins and a variety of biochemical and biophysical techniques we demonstrate a low-affinity, direct interaction between AGO2 and KRAS that is independent of nucleotide. As a separate approach in targeting RAS-driven cancers we demonstrate the development and characterization of a first-in- class EGFR inhibitor that has potent anti-tumor effects against cancers driven by different oncogenes in the MAPK pathway including drug resistant EGFR and mutant RAS. The work presented here provides new mechanistic insight and informs the development of desperately needed therapeutics targeting the EGFR-RAS axis in cancer.PhDCellular & Molec Biology PhDUniversity of Michigan, Horace H. Rackham School of Graduate Studieshttp://deepblue.lib.umich.edu/bitstream/2027.42/176478/1/jwaninge_1.pd
UA1C11/105/10 Phi Mu Composite
No full textPhi Mu Sorority top row l to r: Stephanie Wagner, Peggy DeFreece, Pam Wilmore, Margo Spagnuolo, Belinda Huston, Deborah Brandes, Donna Savage, Dorothy Canada, Melanie Harding. 2nd row l to r: Karen Revell, Lori Campbell, Laura Lafferty, Sharon Redmon, Aleen Davis, Marsha Campbell, Beth Binkley, Mary Thompson. 3rd row l to r: Lori Meyer, Tamela Alldredge, Danna Eberhard, Tonja Coe, Melissa Cox, Michelle Phelps. 4th row l to r: Mary Keilman, Harriet Carter, Joanne Landi, Kerrie Stewart, Sheila Waninger, Laura Ray, Claire Groemling, Jennie Brown. 5th row l to r: Jessica Rappaport, Julia Rather, Karen Strange, Karen Connolly, Elizabeth Baker, Lorri Burchett, Mandy Bivin, Kimberly Logan, Leigh Curtis, Cathy Otto. 6th row l to r: Pam Logsdon, Marian Looney, Susan Hall, Karen Kirsch, Lisa Babcock, Cheryl Warmington, Cindy Strine, Susan Rasbury, Susan brown, Janet West
UA1C11/105/1 Phi Mu Composite
No full textPhi Mu Sorority, top row l to r: Melissa Cox, Leigh Curtis, Libby Baker, Laura Ray, Kimberly Logan, Sheila Waninger, Karen Revell, Cheryl Warmington, Jessica Rappaport, Reta Parker. 2nd row l to r: Jennie Brown, Karen Connelly, Lori Campbell, Dorthy Canada, Claire, Groemling, Lisa Babcock, Lorri Burchett, Karen Strange. 3rd row l to r: Tawny Crawford, Julia Rather, Harriet Carter, Mary Leilman, Mandy Bivin, Jessica Brumley, Rebecca Nixon, Bev Riffle. 4th row l tor: Pam Logsdon, Lynn Stone, Cindy Strine, Susan Brown, Marian Looney, Carole Ware, Kris Patton, Karen Kirsch. 5th row l to r: Karen Riedel, Jennifer Hatfield, Elizabeth McDonald, Heidi Kjellmark, Janetsue West, Pamela Jeter, Lisa Neumann, Robin Hall, Kim Jent, Dawn Simms, Jill Johnson. 6th row l to r: Perry Johnson, Amy Houston, Sandra Morrison, Carol Smith, Lisa Vittitow, Karla Young, Holly Fetherlin, Felicia Eberhard, Gayle Kindred, Audrey Dillman
UA1C11/105/11 Phi Mu Composite
No full textPhi Mu Sorority top row l to r: Lorri Burchett, Jessica Rappaport, Claire Groemling, Leigh Curtis, Cheryl Warmington, Kimberly Logan, Jennie Brown, Mary Keilman, Rebecca Nixon, Sheila Waninger, Libby Baker. 2nd row l to r: Janetsue West, Lynn Stone, Julia Rather, Karen Connolly, Karen Kirsch, Marian Looney, Karen Revell, Cindy Strine, Kris Patton, Tawny Crawford, Karen Strange, Jennifer Hatfield. 3rd row l to r: Patti Wheeler, Kathy Rohleder, Bev Riffle, Pam Logsdon, Carole Ware, Susan Brown, Pamela Jeter, Karen Riedel. 4th row l to r: Perry Johnson, Audrey Dillmann, Felicia Eberhard, Dawn Simms, Lisa Vittitow, Sandy Morrison, Gayle Kindred, Jennifer Daum. 5th row l to r: Lynne Webb, Laura Schroh, Karen Dillmann, Lesley Shelton, Heidi Kjellmark, Mark Ford, Robin Hall, Amy Houston, Amy Anderson, Laura Havens, Mary Coe. 6th row l to r: Michele Whitley, Leslie Allen, Kay Johston, Dawn Gowens, Kellye Curtis, Jenifer Talbott, Ann Logan, Debra Kirsch, Carla Mackey, Autumn Barlow, Tracy Firkins, Elaine Howard. 7th row l to r: Susan Tingle, Wendy Reams, Nancy Kniffen, Jackie Hudson, Jeannie Williams, Jane Mercer, Angie Sawyer, Julia Barry, Jennifer Willard, Tracey Stigletts, Jackie Sundermeier
